# A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct05498428/  
OnCo record `nct05498428` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Amivantamab, Lazertinib, Carboplatin and Pemetrexed in non-small-cell lung cancer, run by Janssen Research & Development, LLC, now recruiting.

## Summary

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT05498428 by Janssen Research & Development, LLC, with 520 participants planned, started 2022-11-11 and due to reach its primary completion in 2027-08-17. Interventions recorded: Amivantamab, Lazertinib, Carboplatin, Pemetrexed, Direct Oral Anticoagulant (DOAC) and Low Molecular Weight Heparin (LMWH).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05498428
- Phase: 2
- Setting: A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 520

## Sources

- ClinicalTrials.gov NCT05498428: https://clinicaltrials.gov/study/NCT05498428

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Amivantamab](https://onco.cc/drugs/amivantamab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Lazertinib](https://onco.cc/drugs/lazertinib/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct05498428.json